Skip to main content

The U.S. Food & Drug Administration (FDA) recently approved Epidiolex oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy. The approval marks the first ever drug comprised of an active ingredient derived from marijuana to be approved by the FDA.

In addition to being the first approved drug with an active ingredient derived from cannabis, the drug is also the first to be approved that is for the treatment of the aforementioned Dravet syndrome. According to statements from the FDA, the move signifies the FDA’s willingness to continue evaluating how some active ingredients in marijuana can help lead to new medical therapies.

The U.S. Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, dietary supplements, prescription and over-the-counter pharmaceutical drugs (medications), vaccines, biopharmaceuticals, medical devices, and other products.

This was reported by FDA on June 25, 2018.

Contact Information: Michael Felderbaum, U.S. Food and Drug Administration; (240) 402-9548; Email: Michael.felderbaum@fda.hhs.gov; Website: www.fda.gov


Tagged As:

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!

Close

Support Request

Need help now?

Call our toll-free phone number 877-350-6463